Boston Scientific Corporation (BSX): Price and Financial Metrics
Boston Scientific Corporation (BSX)
Today's Latest Price: $37.17 USD
Updated Oct 23 7:00pm
Add BSX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
BSX Stock Summary
- BSX has a higher market value than 96.2% of US stocks; more precisely, its current market capitalization is $53,149,563,916.
- Price to trailing twelve month operating cash flow for BSX is currently 38.35, higher than 90.29% of US stocks with positive operating cash flow.
- In terms of volatility of its share price, BSX is more volatile than only 7.59% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Boston Scientific Corp are ABB, PHG, BDX, MELI, and ETN.
- Visit BSX's SEC page to see the company's official filings. To visit the company's web site, go to www.bostonscientific.com.
BSX Stock Price Chart Interactive Chart >
BSX Price/Volume Stats
| Current price | $37.17 | 52-week high | $46.62 |
| Prev. close | $36.86 | 52-week low | $24.10 |
| Day low | $36.71 | Volume | 12,412,633 |
| Day high | $37.41 | Avg. volume | 10,173,118 |
| 50-day MA | $39.48 | Dividend yield | N/A |
| 200-day MA | $37.75 | Market Cap | 53.18B |
Boston Scientific Corporation (BSX) Company Bio
Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. The company was founded in 1979 and is based in Marlborough, Massachusetts.
BSX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $37.17 | $5 | -87% |
Below please find a table outlining a discounted cash flow forecast for BSX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Boston Scientific Corp ranked in the 13th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 86.5%. As for the metrics that stood out in our discounted cash flow analysis of Boston Scientific Corp, consider:
- In the past 5.45 years, Boston Scientific Corp has a compound free cash flow growth rate of 0%; that's higher than only 19.71% of free cash flow generating stocks in the Healthcare sector.
- Boston Scientific Corp's effective tax rate, as measured by taxes paid relative to net income, is at 110 -- greater than 97.55% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -87% |
| 1% | -87% |
| 2% | -87% |
| 3% | -86% |
| 4% | -86% |
| 5% | -86% |
Want more companies with a valuation profile/forecast similar to that of Boston Scientific Corp? See ELAN, EW, TECH, BLFS, and LGND.
Loading social stream, please wait...